Role of T channels in cardiovascular function

Cardiology

Volumn 89, Issue SUPPL. 1, 1998, Pages 2-9

  Hermsmeyer, Kent ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cardiovascular function; L versus T channel selectivity; Mibefradil; T channel calcium blocker

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; MIBEFRADIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD VESSEL WALL; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; CONFERENCE PAPER; CORONARY ARTERY BLOOD FLOW; DIASTOLE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE MASS; HEART MUSCLE OXYGEN CONSUMPTION; HEART PERFUSION; HEART PROTECTION; HEART RATE; HYPERTENSION; INOTROPISM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SUBENDOTHELIUM; SURVIVAL; VASODILATATION;

ANIMALS; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CARDIOVASCULAR PHYSIOLOGY; HEART; HEART FAILURE, CONGESTIVE; HUMANS; MIBEFRADIL; MYOCARDIAL CONTRACTION; MYOCARDIUM; TETRAHYDRONAPHTHALENES;

EID: 0031890679     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047273     Document Type: Conference Paper

References (46)

1. Bean BP: Pharmacology of calcium channels in cardiac muscle, vascular muscle, and neurons. Am J Hypertens 1991;4:406S-411S.
2. Bean BP, Sturek M, Puga A, Hermsmeyer K: Calcium channels in vascular muscle cells isolated from rat mesentcric arteries: Modulation by dihydropyridine drugs. Circ Res 1986;59: 229-235.
3. 2+ Channel Meeting in Montpellier, France. London, Adis, 1997.
4. Bernink PJLM, Prager G, Schelling A, Kobrin I: Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): A new generation of calcium antagonists? Hypertension 1996;27:426-432.
5. 2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol 1995;48:540-549.
6. Billman GE, Hamlin RL: The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation. J Pharmacol Exp Ther 1996;277: 1517-1526.
7. Braun S, van der Wall EE, Emanuelsson H, Kobrin I, on behalf of the Mibefradil International Study Group: Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: A multicenter placebo-controlled study. J Am Coll Cardiol 1996;27:317-322.
8. Bühler FR: Calcium antagonists; in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management, ed 2. New York, Raven, 1995, pp 2801-2814.
9. Clozel JP, Osterrieder W, Kleinbloesem CH, Welker HA, Schläppi B, Tudor R, Hefti F, Schmitt R, Eggers H: Ro 40-5967: A new non-dihydropyridine calcium antagonist. Cardiovasc Drug Rev 1991;9:4-17.
10. de Gasparo M, Bottari S, Levens NR: Characteristics of angiotensin II receptors and their role in cell and organ physiology; in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management, ed 2. New York, Raven, 1995, pp 1695-1720.
11. Folkow B: The structural factor in hypertension with special emphasis on the altered geometric design of the systemic resistance arteries; in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management, ed 2. New York, Raven, 1995, pp 481-502.
12. Godfraind T, Miller R, Wibo M: Calcium antagonism and calcium entry blockade. Pharmacol Rev 1986;38:321-416.
13. Gray GA, Clozel M, Clozel J, Baumgartner H: Effects of calcium channel blockade on the aortic intima in spontaneously hypertensive rats. Hypertension 1993;22:569-576.
14. Hermsmeyer K: Differences of calcium channels in vascular muscle in hypertension. Am J Hypertens 1991;4:412S-415S.
15. Hermsmeyer K: Ion channels as targets for drugs; in Sperelakis N (ed): Cell Physiology Source Book. San Diego, Academic Press, 1995, pp 404-413.
16. Hermsmeyer K, Erne P: Vascular muscle ion channels and cellular calcium regulation in hypertension; in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management, ed 2. New York, Raven, 1995, pp 673-683.
17. 2+ antagonist Ro 40-5967. J Vasc Res 1996;33:71-77.
18. Jackson CL, Schwartz SM: Pharmacology of smooth muscle cell replication. Hypertension 1992;20:713-736.
19. 2+ channels in rat aorta smooth muscle cells in primary culture. Circ Res 1990;67:469-480.
20. Levine TB (for the MACH-1 investigators): The design of the Mortality Assessment in Congestive Heart Failure trial (MACH-1, mibefradil). Clin Cardiol 1997;20:320-326.
21. 2+ channels by Ro 40-5967. J Pharmacol Exp Ther 1994;269:178-183.
22. 2+ channels by Ro 40-5967. Circ Res 1994;75:144-148.
23. 2+ in dog coronary arterial muscle cells by Ro 40-5967. J Cardiovasc Pharmacol 1994; 24:1-7.
24. Mulder P, Richard V, Compagnon P, Henry JP, Lallemand F, Clozel JP, Koen R, Mace B, Thuillez C: Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure. J Am Coll Cardiol 1997;29:416-421.
25. Mulvany MJ: Resistance vessel structure in hypertension: Growth or remodeling? J Cardiovasc Pharmacol 1993;22(suppl 5):S44-S47.
26. Mulvany MJ: Structural changes in the resistance vessels in human hypertension; in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management, ed 2. New York, 1995, pp 503-514.
27. Mulvany MJ, Baumbach GL, Aalkjaer C, Heagerty AM, Korsgaard N, Schiffrin EL, Heistad DD: Vascular remodeling. Hypertension 1996; 28:505-506.
28. Muntinga HJ, Van Der Vring JAFM, Niemeyer MG, Van Den Berg F, Knol HR, Bernink PJLM, Van Der Wall EE, Blanksma PK, Lie K: Effect of mibefradil on left ventricular diastolic function in patients with congestive heart failure. J Cardiovasc Pharmacol 1996;27: 652-656.
29. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res 1993;73:777-782.
30. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol 1989;13:754-759.
31. Rousseau MF, Hayashida W, Van Eyll C, Hess OM, Benedict CR, Ahn S, Chapelle F, Kobrin I, Pouleur H: Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Cardiol 1996;28:972-979.
32. Roux S, Bühler M, Clozel J-P: Mechanism of the anti-ischemic effect of mibefradil, a selective T calcium channel blocker in dogs: Comparison with amlodipine. J Cardiovasc Pharmacol 1996;27:132-139.
33. Rusch NJ, Hermsmeyer RK: Vascular muscle calcium channels in hypertension; in Coca A, Garay RP (eds): Ionic Transport in Hypertension: New Perspectives. Boca Raton, CRC Press, 1994.
34. Ruzicka M, Leenen FHH: Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium antagonists; in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management, ed 2. New York, Raven, 1995, pp 2815-2825.
35. 2+ current amplitudes correlate with lethal increases in blood pressure. J Vase Res 1994;31:359-366.
36. 2+ channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ Res 1994;75: 149-155.
37. Sturek M, Hermsmeyer K: Calcium and sodium channels in spontaneously contracting vascular muscle cells. Science 1986;233:475-478.
38. Stea A, Soong TW, Snutch TP: Determinants of PKC-dependent modulation of a family of neuronal calcium channels. Neuron 1995;15: 929-940.
39. Thybo NK, Korsgaard N, Mulvany MJ: Morphology and function of mesenteric resistance arteries in transgenic rats with low-renin hypertension. J Hypertens 1992;10:1191-1196.
40. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ: Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995;25:174-181.
41. Ting CT, Chen JW, Chang MS, Yin FCP: Arterial hemodynamics in human hypertension: Effects of calcium channel antagonist nifedipine. Hypertension 1995;25:1326-1332.
42. Triggle DJ: Calcium channel drugs: Structure-function relations and selectivity of action. J Cardiovasc Pharmacol 1991;18(suppl 10):S1-S6.
43. 2+ Antagonists in CNS. Branford, Neva Press, 1993, pp 3-13.
44. 2+ channels. Trends Pharmacol Sci 1991;12:349-354.
45. Vacher E, Richer C, Fornes, Clozel J-P, Giudicelli J-F: Mibefradil, a selective calcium T-channel blocker, in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 1996;27:686-694.
46. Vassort G, Alvarez J: Cardiac T-type calcium current: Pharmacology and roles in cardiac tissues. J Cardiovasc Electrophysiol 1994;5:376-393.